Upside – $MEDS +36% (preliminary September pharmacy revenue exceeded $1M, rising more than 66% from July) – $ACN +17% (Q4 beat with $22.2B of bookings and stronger operating margins) – $ABAT +13% (receives federal approval to export up to $100M of recycled black-mass material) – $QSI +13% (no clear fresh catalyst identified; unusually large move …
Read in context ›Monte Rosa Therapeutics Stock (GLUE)
Track Monte Rosa Therapeutics stock through TheStreet Pro's latest coverage, including articles, Daily Diary mentions, TheStreet Pro portfolio activity, contributor watchlist signals, and Pro price levels.
GLUE
Monte Rosa Therapeutics
healthcare
At close
$10.30
â–¼ -0.02 (-0.19%)
Oct 9, 4:00 PM ET
After-hours
$10.30
• +0.00 (0.00%)
Oct 9, 7:35 PM ET
Market Cap
$878.73M
P/E Ratio
—
1Y Return
+21.75%
EPS (TTM)
-$1.91
Read the latest TheStreet Pro articles mentioning Monte Rosa Therapeutics, including market roundups, portfolio updates, trade ideas, and investing analysis.
Articles
0 articlesNo articles mentioning GLUE yet.
Daily Diary Mentions
1 mentionUpside, Downside Movers in the Morning